The ability of tumour cells to resist apoptosis-inducing signals by cytotoxic T cells may decide the success or failure of tumour elimination. An important effector of apoptosis is the CD95/CD95 ligand system (APO-1/Fas) that mediates perforin-independent cytotoxic T-cell killing of tumour cells. We propose a new strategy by which tumour cells can resist CD95-induced apoptosis. We identified matrix metalloproteinase-7, MMP-7 (Martilysin), as the first physiologically relevant protease that can specifically cleave CD95. MMP-7 is of unique importance because it is produced by the tumour cells themselves at early stages of tumour development. Microsequencing of the positions in CD95 cleaved by MMP-7 revealed two sites in the N-terminal extracellular domain of CD95, important for preligand assembly of CD95. MMP-7 cleavage of CD95 results in reduced CD95 surface expression and decreased CD95-mediated apoptosis sensitivity of tumour cells. Treatment of MMP-7-positive HT-29 tumour cells with MMP-7-antisense oligonucleotides led to an increase in CD95-mediated apoptosis sensitivity. Finally, specific cytotoxic T-cell killing was reduced in the presence of MMP-7. Thus, MMP-7 expression in tumour cells may contribute to an apoptosisresistant phenotype, which ultimately promotes immune escape. This activity may account for the well-established role of MMP-7 in early tumour development.
Alterations in the control of apoptosis mediated through the CD95 system contribute to the pathogenesis of a number of disorders such as cancer, autoimmunity, AIDS and liver diseases (Galle et al., 1995; Strand et al., 1996; Kondo et al., 1997; Strand et al., 1998; Krammer, 2000) . Decreased sensitivity to CD95-mediated apoptosis is a common trait shared by many cancer cells, which provides them with critical survival advantages ultimately promoting malignancy (Khong and Restifo, 2002) . Tumours are potentially antigenic, so that the immune system is capable of recognizing and destroying these abnormal cells (Dunn et al., 2002) . Thus, the ability of tumour cells to resist apoptosis-inducing signals may decide the success or failure of tumour elimination. Cytotoxic T lymphocytes (CTLs) have been consistently implicated in tumour surveillance and regression leading to the development of immunological-based cancer therapies founded on these principles (Theobald et al., 1995; Rosenberg, 1999) . The efficacy of these strategies depends on the apoptosis-inducing function of CTLs that occurs primarily through both the CD95-and perforin systems (Shresta et al., 1998; Medema et al., 1999; Seki et al., 2002) . Loss of CD95 expression and expression of soluble CD95 (sCD95) contribute to the immune escape of tumour cells and are correlated with poor prognosis (Nonomura et al., 2000; Mizutani et al., 2001; Osorio et al., 2001; Ugurel et al., 2001) . Here, we propose a new strategy by which tumour cells can resist CD95-induced apoptosis; namely, by cleavage of CD95 by matrix metalloproteinase-7 (Matrilysin/MMP-7).
Matrilysin/MMP-7 is distinguished from other MMP family members as being the smallest member containing only the common catalytic domain and Zn 2 þ binding region, but lacking the haemopexin-like domain common to other MMPs. Along with its prometastatic function, a fundamental role for MMP-7 has also been established in early tumour development (Egeblad and Werb, 2002) . Ablation of MMP-7 in a mouse model for intestinal cancer reduced tumour formation by 67% (Wilson et al., 1997) . On the other hand, overexpression of MMP-7 in MMTV-neu mice, a mouse model for mammary tumorigenesis, significantly promoted tumour development in mammary glands (Rudolph-Owen et al., 1998) . The mechanism by which MMP-7 contributes to early tumour growth is still unknown. We analysed the influence of MMP-7 on CD95-mediated apoptosis, with particular attention to the CD95 receptor and the cytotoxic action of specific T cells.
MMP-7 specifically cleaves CD95
We expressed recombinant CD95 protein in Escherichia coli and incubated the purified protein with six different MMPs, MMP-2, -3, -7, -8, -9 and -10. The ability of these MMPs to cleave CD95 was analysed by SDS-PAGE and Western blot. Lower molecular mass bands for CD95, indicative of proteolysis, were observed only after MMP-7 treatment (Figure 1a) . To examine the specificity of the reaction, we incubated CD95 protein with the MMP-7 inhibitor, N-hydroxy-1,3-di-(4-methoxybenzenesulphonyl)-5,5-dimethyl-1,3-piperazine-2-carboxamide (Inhibitor II) alone and in combination with MMP-7 (Pikul et al., 1998) . Cleavage of CD95 by MMP-7 was inhibited by Inhibitor II, indicating specific proteolysis (Figure 1b) . The positions in CD95 cleaved by MMP-7 were determined by microsequencing. Two positions at CD95 amino acids 20 and 33 are the specific cleavage sites for MMP-7 (Figure 1c ). Both cleavage products contain leucine in the NH 2 -terminal position (P1 0 ), which is consistent with previous studies determining the MMP-7 target site specificities. A review of the protein sequences cleaved by MMP-7 revealed that 21 of 32 proteins were cleaved at positions that left leucine/isoleucine residues at P1 0 (Woessner and Nagase, 2000). Truncation of CD95 at these sites removes 20 and 33 amino acids from the mature CD95 protein and deletes part of a recently described domain for selfassociation termed 'preligand assembly domain' (PLAD) (Figure 1c ). The PLAD domain has been shown to facilitate oligomerization of CD95 receptors before ligand binding (Siegel et al., 2000) . According to current models, preassembly of CD95 receptors may be a key step in regulating CD95 signalling. Support for this notion comes from studies in which mutated CD95 molecules can dominantly interfere with CD95-mediated apoptosis through PLAD-mediated association between wild-type and mutant receptors (Siegel et al., 2000) .
MMP-7 decreases CD95 apoptosis sensitivity
To explore the functional effects of MMP-7 activity on CD95-mediated apoptosis, we first measured CD95 surface expression in HepG2 hepatoblastoma cells treated with MMP-7. Upon treatment with MMP-7, CD95 surface expression was reduced in comparison to a control protein also located on the surface, GP130 (Figure 2a) . Next, we analysed the effects on apoptosis induction by treating HepG2 cells with MMP-7 and by triggering apoptosis with agonistic anti-APO-1 antibodies, CD95 ligand or TRAIL (Figure 2b and c). After pretreatment with MMP-7, HepG2 as opposed to control cells were resistant to CD95-mediated apoptosis, indicating that loss of CD95 through MMP-7 cleavage attenuates apoptosis induction. TRAIL-mediated apoptosis was not affected, suggesting that MMP-7 does not interfere with apoptotic pathways in general. To test whether cytolytic effector functions of CTLs are influenced by MMP-7, we performed coculture experiments with antigen-specific HLA-A*0201-restricted cytotoxic T lymphocytes and HepG2 or HEK-293 cells as targets (Theobald et al., 1995) . We found a substantial decrease in the cytotoxic action of T cells in the presence of MMP-7 (Figure 2d ).
MMP-7 inhibition restores CD95 apoptosis sensitivity
To further define the functional interaction between MMP-7 and CD95, we treated the constitutively MMP-7-positive colon carcinoma cell line HT29 with antisense oligonucleotides for MMP-7 and measured the coli as a his-tag fusion protein and purified by standard methods. Its chimeric nature was confirmed by immunoblotting with polyclonal anti-CD95 antibodies to the human CD95 protein (Ab-1, Oncogene). Amino-acid sequences of native amino termini were determined using a 477A protein sequencer apparatus from Applied Biosystems with a Blot-cartridge device MMP-7 cleaves CD95 S Strand et al CD95-mediated apoptosis sensitivity. HT-29 cells treated with antisense MMP-7 oligonucleotides showed an increased apoptosis sensitivity (Figure 3a) . In reciprocal experiments, we expressed MMP-7 in MMP-7 negative, CD95-positive HEK-293 cells using an ecdysone-regulated promoter. The induction of MMP-7 reduced the sensitivity to CD95-mediated apoptosis (Figure 3b) . Additionally, HT29 cells treated with the MMP-7 inhibitor showed increased CD95 expression. (Figure 3c ). This was confirmed in coculture experiments with p53.264-272 peptide-specific CTLs and HT29 target cells. Upon treatment with MMP-7 Inhibitor II, HT29 targets showed an increase in Cr release assays were performed to quantify apoptosis induction in p53.264-272 peptidepulsed HepG2 targets. A2.1-restricted effector cells were A2.1 and CD8 Â A2.1 transgenic mice-derived CTLs specific for human p53.264-272 (CTL A2 p53.264) and (CTL CD8 Â A2 p53.264). All experiments were repeated at least three times with similar results. CD8 Â A2 p53.264 CTLs were obtained from double transgenic mice for human CD8 and HLA-A2.1 (Lustgarten et al., 1997) . The peptide specificity of the p53.264 CTLs was controlled by their failure to lyse target cells loaded with an irrelevant peptide MMP-7 cleaves CD95 S Strand et al CTL-mediated apoptosis (Figure 3d ). Our results demonstrate that inhibition of endogenous MMP-7 expression can enhance CD95 surface expression and sensitivity of tumour cells towards cytotoxic action of T cells. These findings define a causal relationship between MMP-7 expression and apoptosis resistance of tumour cells. MMPs have emerged as important targets for cancer therapy. The rationale behind these therapies is based on the role of MMPs in remodelling the extracellular matrix, thus promoting invasion and metastasis. The limited success of MMP inhibitors in clinical trials has led to a rethinking of the simplistic rationales behind these therapies. Several explanations have been put forth, including the idea that MMP inhibitors may be more effective in earlier stages of cancer progression so that the expected benefits during later cancer stages, where the clinical studies were performed, might not be realized. Consistent with these ideas are the recent data that have extended the targets of MMPs beyond matrix components to nonmatrix substrates, which under pathological circumstances, may contribute to tumour progression early on. A role for MMP-7 in early tumour development has been documented, but the mechanisms underlying these effects are not clear. One of the hallmarks of tumour cells is apoptosis resistance. Our results demonstrate a mechanism by which tumour cells may become apoptosis resistant, namely through cleavage of CD95 by MMP-7. The effect of shedding CD95 ligand (CD95L) has been investigated previously, and more recently the shedding of CD95L by MMP-7 (Tanaka et al., 1998; Powell et al., 1999; Fingleton et al., 2001; Mitsiades et al., 2001; Vargo-Gogola et al., 2002) . Both pro-and antiapoptotic activities of MMP-7-shedded CD95L have been reported. According to recent work, MMP-7 cleavage of CD95L produces soluble CD95L that is capable of activating CD95 apoptosis (Fingleton et al., 2001) . Conflicting evidence has been presented, demonstrating that soluble CD95L after MMP-7 cleavage impairs the apoptosis-inducing activities of chemotherapeutic drugs (Mitsiades et al., 2001) . Although these results indicate that MMP-7 can influence the CD95 system and contributes to tumour development, the role of MMP-7 in the CD95 receptor has been largely ignored. Our results demonstrate a more direct effect of MMP-7 for developing apoptosis resistance through cleavage of the CD95 receptor from the surface of the tumour cell. The consequence for the tumour cell is insensitivity to CD95 ligand regardless of its activity or source. The well-documented MMP-7 expression in tumour cells and the correlation of MMP-7 expression with poor prognosis are important parameters consistent with the notions presented in this paper.
Studies to unravel the molecular mechanisms of apoptosis resistance may help in the design of new strategies for cancer treatment. Our findings offer a perspective for tumour therapy based on the direct interference with the apoptosis resistance of malignant cells. The novel mechanism of apoptosis resistance as defined in this report also has tremendous consequences for the development of cancer immunotherapies, such as optimized antitumour vaccination strategies.
